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In conclusion, 6 months of treatment with carvedilol in patients with is-
chemic heart failure resulted in improved ejection fraction and reduced LV
chamber dimensions. However, there were no detectable changes in maxi-
mal or submaximal exercise performance or in NYHA class.
*p < 001; t p ~ 004; all others NS. EF ~ ejection fraction, LV = left ventricular, EDD ~
end-diastolic dimension, ESD = end-systolic dimension
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1707-21 Effects of Carvedilol on Left Ventricular Function and
Exercise Performance in Patients with Heart Failure
of Ischemic Etiology
Stephen MacMahon, Robert Doughty, Norman Sharpe, ANZ Heart Failure
Research Collaborative Group. University ofAuckland, Auckland, New Zealand
Results from several small trials in patients with heart failure of predom-
inantly idiopathic etiology suggest that beta-blocker therapy may improve
ventricular function, but the effects on exercise performance remain less
certain. To determine the effects of such treatment in patients with heart
failure of ischemic etiology, patients with this condition and ejection fraction
(EF) <45% were randomized to treatment with carvedilol (12.5-50 mg/day)
or placebo. Prior to randomization, 444 patients entered a 2-3 week run-in
phase on open label, low-dose carvedilol (6.25-12.5 mg/day). 415 patients
(93%) were randomized. Primary outcome variables were radionuclide mea-
surements of EF and measurements of treadmill exercise duration (TED) us-
ing a modified Naughton protocol. Secondary outcomes included leftventric-
ular chamber dimensions measured by M-mode echocardiography, submax-
imal exercise performance assessed from 6 minute walk distance (6 MWO)
and NYHA functional class. After 6 months, resting heart rate was reduced by
7.1 bpm, and blood pressure was reduced by 5.1 /4.5 mmHg in the carvedilol
group compared to the placebo group. Results for the main outcomes are
shown below as differences between carvedilol and placebo groups after 6
months of follow-up.
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1707-31 CISIS Left Ventricular Function Sub-study: Analysis
of Predictive Factors of Initial Improvement and
Prognostic Value
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* p < 0.05 vs. placebo
Hong Han. Barbara Braeker, Stefan Neubauer, Georg Ertl. Department ofMedicine,
Wiirzburg University, FRG
Using specific Endothelin-l (ET-1) antagonists B0123 and B061 0, we tested
whether endogenous ET-1 contributes to ischemia/reperfusion injury in iso-
lated, Langendorff-perfused rat hearts. B0123 (7 J.Lg/min) and B0610 (1.75
/Lg/min) did not affect mechanical function or coronary flow and shifted the
dose-response curve for ET-1 significantly to the right. Isovolumic rat hearts
were pre-treated with B0123, B0610 or saline for 10 min, and were sub-
jected to 30 min ischemia followed by reperfusion. At 15 min ischemia,
the increase of left ventricular resting pressure (mmHgl was significantly re-
duced by BO 123(17 ± 3*; n ~ 11) and B0610(17 ± 3*; n = 12) compared to
saline (45 ± 7; n = 12). During reperfusion, recovery of left ventricular devel-
oped pressure (mmHg) was improved with B0123 123 ± 7*) and B061 0 (20
± 3*) compared to saline (10 ± 3). In hearts pre-treated with B0610, high-
energy phosphate metabolism was continuously recorded with 31P-NMR
spectroscopy (n Bruker NMR System). ATP content (% of control) at 30 min
ischemia was higher with B0610 (20 ± 3*; n = 11) compared to saline (5 ±
2; n ~ 8), and creatine phosphate recovery (% of control) was improved with
B0610 during reperfusion (76 ± 7* vs 54 ± 6 with saline). Thus, endogenous
ET-1 contributes to ischemia/reperfusion injury. Specific ET-1 antagonists at-
tenuate functional and metabolic consequences of ischemia/reperfusion in-
jury without affecting pre-ischemic workload.
*p < 0.05 vs. saline.
Despite a short half-life of less than 30 minutes, CGRP caused a signif-
icantly more rapid return of cardiac function from ischemia than placebo
throughout the entire 24 hours of reperfusion. These results suggest that
CGRP may improve recovery from reversible myocardial ischemia and may
have unique properties as an intravenous inotrope in an intensive care unit
setting because it does not appear to impair recovery from acute myocardial
ischemia.
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Endothelin-1 Receptor Antagonists SQ123 and
BQ610 Delay Ischemic Contracture, Preserve
High-Energy Phosphate Metabolism and Improve
Systolic Function During Ischemia/Reperfusion
Placebo
CGRP
trol) ± SEM for the 9 dogs.
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1707-1 I Short-term ACE-Inhibition and Onset and
Progression of Congestive Heart Failure in Patients
with Acute Myocardial Infarction
Claudio Borghi, Ettore Ambrosioni, Bruno Magnani, SMILE Investigators.
University ofBologna, Bologna, Italy
Anterior acute myocardial infarction (AMI) is often complicated by clinical
signs of CHI' We report the data of 1146 patients with anterior AM.1. with-
out previous history or clinical signs of CHF on admission and enrolled un-
der the SM/LE study. Patients were randomly allocated to a 6-week double-
blind treatment with placebo (P) or zofenopril (ZI and then followed-up for 1
year. Baseline demographic characteristics were similar in Z and Pgroup who
were comparable for blood pressure, ECG pattern, peak CPK, and concomi-
tant drug treatment. After 6 weeks the cumulative occurrence of CHF was
not different in Z and P groups (13.3% vs 13.9%; P = 0.234). Clinical signs of
mild to moderate CHF were present in 11.7% ofthe Z population and 10.2%
of the P group (P = 0.178) whereas severe refractory CHF occurred signif-
icantly less in Z (1.6%) compared to P (3.6%) patients (RR = 2.3: C.1. 95%
1-3.3: p = 0.0328). After 1 year the overall occurrence of CHF was 14.8% in
P and 15.4% in Z treated patients. NYHA class I was more common among
Z treated patients (8.2% vs 1.5%; P = 0.021) whereas the percentage of pa-
tients in NYHA class IV was higher in P treated patients (24.3% vs 11.0%;
p = 0.001). In conclusion the early and long-term development and progres-
sion of CHF can be prevented by short-term administration of zofenopril in
patients with acute myocardial infarction.
Philippe Lechat, Herve Lardoux, Jean-Pierre Boissel, Serge Witchitz, Martin Hetzel,
Luigi Ciampricotti, Eric Chanton, Christian Mesenge, Patrice Jaillon, CIBIS
Investigators. ClBIS Coordinating Center, Pitie-5alpetr;';'re Hospital, Paris, France
During the Cardiac Insufficiency Bisoprolol Study (CiBIS) which evaluated
beta-blockade IBB) effects on mortality in 641 patients (pts) with heart fail-
ure (mean follow up: 1.9 ± 0.8 years, SO), we studied the determinants of
BB induced improvement of left ventricular function (LVFL the mechanism
of which remains unclear. Echocardiographic assessment of LVF was per-
formed at baseline (BL) in all patients and in a subgroup of 164 patients 183
on B, 81 on P) still alive 5 months after inclusion. All patients received a back-
ground diuretic and vasodilator therapy and were blindly randomized either
to placebo (P) or to bisoprolol (B). Among these 164 pts, a similar proportion
in both groups presented with left bundle branch block (23 on P. 22 on B, NS)
or chronic atrial fibrillation (15 on P. 10 on B, NS). According to all recorded
parameters at baseline, this subgroup of pts was representative of the entire
CIBIS population. Results (means ± SD):
EDD Icm) ESD (cm) FS(%I
BL P 68 ± 0.9 5.7 ± 0.9 16.8 ± 46
B 69 ± 0.8 5.8 ± 08 155 ± 5.0
5M P 6.8 ± 1.0 57 ± 1.0 16.8 ± 5.8
B 6.7 ± 0.9 5.4± 1* 20.1 ± 7.0**
EDD ~ end diastolic diameter; ESD ~ end systolic diameter; FS ~ fractional shortening;
* p ~ 0.07; •• p = 0.001
LVFS significantly improved on Bat 5 months compared to P (LVFS varia-
tion was: -0.04 ± 5.5% with P and +4.6 ± 6.5% with B, p < 0.001). Such im-
provement was similar in ischemic and non ischemic pts. It was uncorrelated
to other BL parameters and to B induced bradycardia (-18 ± 12 beats/min at
5 ML but it was significantly correlated with survival after the initial 5 month
period (Cox model, 12 patients died on P. 7 on B, p = 0.01).
We conclude that echocardiographic LVFS improvement on B is an inde-
pendent marker of BB action in heart failure appears uncorrelated to baseline
parameters but is associated with a better prognosis.
